156 related articles for article (PubMed ID: 20862594)
1. Rational questing for potential novel inhibitors of FabK from Streptococcus pneumoniae by combining FMO calculation, CoMFA 3D-QSAR modeling and virtual screening.
Zhang Q; Yu C; Min J; Wang Y; He J; Yu Z
J Mol Model; 2011 Jun; 17(6):1483-92. PubMed ID: 20862594
[TBL] [Abstract][Full Text] [Related]
2. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
3. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K
Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940
[TBL] [Abstract][Full Text] [Related]
4. Phenylimidazole derivatives as new inhibitors of bacterial enoyl-ACP reductase FabK.
Kitagawa H; Ozawa T; Takahata S; Iida M
Bioorg Med Chem Lett; 2007 Sep; 17(17):4982-6. PubMed ID: 17600706
[TBL] [Abstract][Full Text] [Related]
5. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor.
Saito J; Yamada M; Watanabe T; Iida M; Kitagawa H; Takahata S; Ozawa T; Takeuchi Y; Ohsawa F
Protein Sci; 2008 Apr; 17(4):691-9. PubMed ID: 18305197
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.
Lu X; Lv M; Huang K; Ding K; You Q
Int J Mol Sci; 2012; 13(6):6620-6638. PubMed ID: 22837653
[TBL] [Abstract][Full Text] [Related]
8. Atromentin and leucomelone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae.
Zheng CJ; Sohn MJ; Kim WG
J Antibiot (Tokyo); 2006 Dec; 59(12):808-12. PubMed ID: 17323650
[TBL] [Abstract][Full Text] [Related]
9. AG205, a novel agent directed against FabK of Streptococcus pneumoniae.
Takahata S; Iida M; Osaki Y; Saito J; Kitagawa H; Ozawa T; Yoshida T; Hoshiko S
Antimicrob Agents Chemother; 2006 Aug; 50(8):2869-71. PubMed ID: 16870790
[TBL] [Abstract][Full Text] [Related]
10. 3D-QSAR studies on triclosan derivatives as Plasmodium falciparum enoyl acyl carrier reductase inhibitors.
Shah P; Siddiqi MI
SAR QSAR Environ Res; 2010 Jul; 21(5-6):527-45. PubMed ID: 20818586
[TBL] [Abstract][Full Text] [Related]
11. Crystallization and preliminary X-ray analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae.
Saito J; Yamada M; Watanabe T; Kitagawa H; Takeuchi Y
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2006 Jun; 62(Pt 6):576-8. PubMed ID: 16754986
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK).
Marrakchi H; Dewolf WE; Quinn C; West J; Polizzi BJ; So CY; Holmes DJ; Reed SL; Heath RJ; Payne DJ; Rock CO; Wallis NG
Biochem J; 2003 Mar; 370(Pt 3):1055-62. PubMed ID: 12487627
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new potential hits of Plasmodium falciparum enoyl-ACP reductase through ligand- and structure-based drug design approaches.
Neves BJ; Bueno RV; Braga RC; Andrade CH
Bioorg Med Chem Lett; 2013 Apr; 23(8):2436-41. PubMed ID: 23499236
[TBL] [Abstract][Full Text] [Related]
14. Virtually Designed Triclosan-Based Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis and of Plasmodium falciparum.
Owono Owono LC; Ntie-Kang F; Keita M; Megnassan E; Frecer V; Miertus S
Mol Inform; 2015 May; 34(5):292-307. PubMed ID: 27490275
[TBL] [Abstract][Full Text] [Related]
15. Combined 3D-QSAR and Molecular Docking Study for Identification of Diverse Natural Products as Potent Pf ENR Inhibitors.
Wadhwa P; Saha D; Sharma A
Curr Comput Aided Drug Des; 2015; 11(3):245-57. PubMed ID: 26517356
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
17. Panosialins, inhibitors of enoyl-ACP reductase from Streptomyces sp. AN1761.
Kwon YJ; Sohn MJ; Oh T; Cho SN; Kim CJ; Kim WG
J Microbiol Biotechnol; 2013 Feb; 23(2):184-8. PubMed ID: 23412060
[TBL] [Abstract][Full Text] [Related]
18. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
19. Design of inhibitors of the MurF enzyme of Streptococcus pneumoniae using docking, 3D-QSAR, and de Novo design.
Khedkar SA; Malde AK; Coutinho EC
J Chem Inf Model; 2007; 47(5):1839-46. PubMed ID: 17663541
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of
Mahfuz AMUB; Stambuk Opazo F; Aguilar LF; Iqbal MN
J Biomol Struct Dyn; 2022 Jun; 40(9):4021-4037. PubMed ID: 33251968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
